|
Aug 6
|
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
|
|
Aug 1
|
BC-Most Active Stocks
|
|
Aug 1
|
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
|
|
Jul 21
|
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®
|
|
Jul 14
|
FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks
|
|
Jul 11
|
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress
|
|
Jul 1
|
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
|
|
May 27
|
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
|
|
May 27
|
BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
|
|
Mar 11
|
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
|
|
Jul 30
|
BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
|
|
Jul 16
|
BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
|
|
Jun 25
|
BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
|
|
May 10
|
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
|
|
May 10
|
BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations
|
|
May 10
|
Q1 2024 BioXcel Therapeutics Inc Earnings Call
|
|
May 9
|
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
|
|
Apr 25
|
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
|
|
Apr 24
|
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
|
|
Apr 22
|
BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
|